Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
The postabsorptive urinary total (T), dialyzable (D), and nondialyzable (ND) hydroxyproline (HYPRO) tests were evaluated to determine whether the patterns of excretion varied according to the predominance of osteoblastic v osteolytic bone involvement in 58 patients with neoplastic disease. In patients with osteolytic lesions from multiple myeloma, elevated T and D levels with normal ND HYPRO values were observed, along with elevated D/ND ratios. In prostate cancer, the T, D, and ND values were all elevated and the D/ND ratio was normal. Patients with Hodgkin's disease had elevated T, D, and ND HYPRO levels, and the D/ND ratio was in the range of patients with prostate cancer. The data suggest that these collagen markers may be useful in the long-term evaluation of these neoplasms in patients.
D001859:Bone Neoplasms / Q000556:secondary / Q000652:urine*; D001943:Breast Neoplasms; D003094:Collagen / Q000652:urine; D003956:Dialysis; D005260:Female; D006689:Hodgkin Disease / Q000556:secondary*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008297:Male; D009101:Multiple Myeloma / Q000556:secondary*; D011471:Prostatic Neoplasms
D003094:Collagen; D006909:Hydroxyproline